このページの翻訳は実験的なもので、現在開発中です。お待ちしております

BioHarvest Sciences マネジメント

マネジメント基準チェック /34

BioHarvest Sciences'の CEO はIlan Sobelで、 Jun2020年に任命され、の在任期間は 4.08年です。は、会社の株式の1.25%を直接所有しており、その価値はCA$ 1.82M 。経営陣と取締役会の平均在任期間はそれぞれ4.1年と3.8年です。

主要情報

Ilan Sobel

最高経営責任者

US$481.6k

報酬総額

CEO給与比率	n/a
CEO在任期間	4.3yrs
CEOの所有権	1.3%
経営陣の平均在職期間	4.3yrs
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

BioHarvest Sciences Inc.'s (CSE:BHSC) P/S Is On The Mark

Mar 17

Investors Interested In BioHarvest Sciences Inc.'s (CSE:BHSC) Revenues

Dec 01

Don't Ignore The Fact That This Insider Just Sold Some Shares In BioHarvest Sciences Inc. (CSE:BHSC)

Jan 17

How Much Of BioHarvest Sciences Inc. (CSE:BHSC) Do Insiders Own?

Jan 10

CEO（最高経営責任者

Ilan Sobel

4.3yrs

在職期間

US$481,581

報酬

Mr. Ilan Sobel has been the Chief Executive Officer at BioHarvest Sciences Inc. since June 9, 2020. He served as Chief Operating Officer at Weissbeerger Ltd. and then Chief Commercial Officer of Weissbeerg...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Zaki Rakib	Co-Founder	6.1yrs	US$1.16m	データなし
Ilan Sobel	Chief Executive Officer	4.3yrs	US$481.58k	1.25% $ 1.7m
Yochi Hagay	Co-Founder	6.1yrs	US$67.02k	0.18% $ 245.7k
Alan Rootenberg	Chief Financial Officer	6yrs	US$31.48k	0.0078% $ 10.5k
Ilana Belzer	Chief Operating Officer	1.5yrs	US$275.09k	0.0032% $ 4.2k
David Ryan	VP of Investor Relations & Secretary	11.5yrs	US$44.45k	0.23% $ 302.4k
Brian Cornblatt	Chief Medical Officer & Member of Scientific Advisory Board	2.6yrs	US$421.35k	0.015% $ 19.9k
Matthew Zrebiec	Vice President of Business Development	less than a year	データなし	データなし

4.3yrs

平均在職期間

65yo

平均年齢

経験豊富な経営陣: BHSCの経営陣は経験豊富であると考えられます ( 4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Zaki Rakib	Co-Founder	6.1yrs	US$1.16m	データなし
Yochi Hagay	Co-Founder	3.8yrs	US$67.02k	0.18% $ 245.7k
Brian Cornblatt	Chief Medical Officer & Member of Scientific Advisory Board	1.8yrs	US$421.35k	0.015% $ 19.9k
Steven Lehrer	Member of Board of Advisor	3yrs	データなし	データなし
Vincent Giampapa	Member of Scientific Advisory Board	no data	データなし	データなし
Dennis Goodman	Member of Scientific Advisory Board	3.8yrs	データなし	データなし
David Tsur	Independent Non-Executive Director	3yrs	US$37.36k	データなし
David Brady	Member of Scientific Advisory Board	4yrs	データなし	データなし
Scott McCune	Member of Advisory Board	3.6yrs	データなし	データなし
Vivien Rakib	Independent Director	6.1yrs	US$26.65k	17.5% $ 23.5m
John Fiddick	Independent Director	5.7yrs	US$26.65k	データなし
Roberto Chait	Member of Advisory Board	4yrs	データなし	データなし

3.8yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: BHSCの取締役会は経験豊富であると考えられます ( 3.7年の平均在任期間)。

BioHarvest Sciences マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Bioharvest Sciences Inc. Announces Resignation of David Ryan as Director

BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024

BioHarvest Sciences Inc. Announces Appointment of John Paul Sangiovanni as Medical and Scientific Advisory Board

BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023

Bioharvest Sciences Inc. Appoints George Garibaldi to its Scientific Board of Advisors

No independent directors

Recent updates

Bioharvest Sciences Inc. Announces Resignation of David Ryan as Director

Second quarter 2024 earnings released: US$0.042 loss per share (vs US$0.21 loss in 2Q 2023)

New major risk - Financial position

New minor risk - Market cap size

BioHarvest Sciences Inc. announced that it expects to receive CAD 6.847977 million in funding

First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.057 loss in 1Q 2023)

Full year 2023 earnings released: US$0.027 loss per share (vs US$0.025 loss in FY 2022)

BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024

BioHarvest Sciences Inc.'s (CSE:BHSC) P/S Is On The Mark

BioHarvest Sciences Inc. to Report Q4, 2023 Results on Mar 29, 2024

BioHarvest Sciences Inc. announced that it has received CAD 13.622872 million in funding

Bioharvest Sciences Inc. Announces Major Product Launch of Vinia-Based Functional Coffee Products

Investors Interested In BioHarvest Sciences Inc.'s (CSE:BHSC) Revenues

Bioharvest Sciences Inc. Revises Revenue Guidance for the Year 2023

BioHarvest Sciences Inc. announced that it expects to receive CAD 12 million in funding

Second quarter 2023 earnings released: US$0.006 loss per share (vs US$0.005 loss in 2Q 2022)

BioHarvest Sciences Inc. to Report Q2, 2023 Results on Aug 30, 2023

BioHarvest Sciences Inc. announced that it expects to receive CAD 4.625103 million in funding

BioHarvest Sciences Inc. Announces Appointment of John Paul Sangiovanni as Medical and Scientific Advisory Board

Bioharvest Sciences Inc. Reiterated Sales Guidance for the year 2023

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.005 loss in 1Q 2022)

BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023

Full year 2022 earnings released: US$0.025 loss per share (vs US$0.023 loss in FY 2021)

BioHarvest Sciences Inc. Announces Clinical Study in Patients with Multiple Sclerosis-Related Optic Neuritis

Bioharvest Sciences Inc. Appoints George Garibaldi to its Scientific Board of Advisors

BioHarvest Sciences Inc. announced that it has received CAD 10.03355 million in funding

Bioharvest Sciences Inc. Provides Revenue Guidance for the Year 2022 and 2023

Third quarter 2022 earnings released: US$0.009 loss per share (vs US$0.007 loss in 3Q 2021)

No independent directors

Second quarter 2022 earnings released: US$0.005 loss per share (vs US$0.004 profit in 2Q 2021)

BioHarvest Sciences Inc. Appoints Gavriel Lambert to its Board of Advisors

Bioharvest Sciences Inc. Hires Dr. Brian S. Cornblatt as Chief Medical Officer

First quarter 2022 earnings released: US$0.005 loss per share (vs US$0.016 loss in 1Q 2021)

Full year 2021 earnings released: US$0.023 loss per share (vs US$0.019 loss in FY 2020)

No independent directors

BioHarvest Sciences Inc. announced that it expects to receive CAD 6.3 million in funding

BioHarvest Sciences Inc. Reiterates Sales Orders Guidance for 2022

BioHarvest Sciences Inc. Provides Revenue Guidance for the Year 2022

Third quarter 2021 earnings: Revenues in line with analyst expectations

Second quarter 2021 earnings released: EPS US$0.004 (vs US$0.004 loss in 2Q 2020)

Bioharvest Sciences Inc. Unveils New Groundbreaking Cannabis Trichome Structure

BioHarvest Sciences Inc. announced that it expects to receive CAD 4 million in funding

BioHarvest Sciences Inc. Reveals Vinia Anti-Aging Capabilities Via Blood Flow Improvement

First quarter 2021 earnings released

Full year 2020 earnings released

Bioharvest Sciences Inc. Unveils Unique Polyphenolic Content of Its Upcoming Olive Based Nutraceutical

Bioharvest Sciences Inc. Announces Partnership with Boldt and Summit Strategy Group to Develop A Sustainability Framework and Esg Report

New 90-day high: CA$0.57

BioHarvest Sciences Inc. Announces a Major Breakthrough in the Growth of Cannabis TRICHOMES across Multiple Strains in Liquid Media

BioHarvest Sciences Inc. announced that it has received CAD 6.179932 million in funding

BioHarvest Sciences Inc. announced that it expects to receive CAD 6 million in funding

New 90-day high: CA$0.43

Don't Ignore The Fact That This Insider Just Sold Some Shares In BioHarvest Sciences Inc. (CSE:BHSC)

BioHarvest Sciences Inc. Appoints Dennis Goodman to Its Scientific Advisory Board

How Much Of BioHarvest Sciences Inc. (CSE:BHSC) Do Insiders Own?

New 90-day high: CA$0.21

Third quarter 2020 earnings released: US$0.004 loss per share

BioHarvest Sciences Inc. Announces the Appointment of Rhona Applebaum as Its Senior Consultant for Regulatory and Environmental Affairs

BioHarvest Sciences Inc. Appoints Roberto Chait to Advisory Board

BioHarvest Sciences Inc. announced that it has received CAD 3.807759 million in funding

BioHarvest Sciences Inc. Signs Exclusive Sales and Distribution Agreement with Batory Foods

BioHarvest Sciences Inc. announced that it expects to receive CAD 3.814208 million in funding

First half earnings released

BioHarvest Sciences Inc. announced that it has received CAD 0.652379 million in funding

BioHarvest Ltd. completed the acquisition of Canna-V-Cell Sciences Inc. (CNSX:CNVC) in a reverse merger transaction.

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

マネジメント基準チェック /34